These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 18980023)

  • 1. Trastuzumab: mechanisms of resistance and therapeutic opportunities.
    Calabrich A; Fernandes Gdos S; Katz A
    Oncology (Williston Park); 2008 Oct; 22(11):1250-8; discussion 1259, 1263. PubMed ID: 18980023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].
    Dieras V; Vincent-Salomon A; Degeorges A; Beuzeboc P; Mignot L; de Cremoux P
    Bull Cancer; 2007 Mar; 94(3):259-66. PubMed ID: 17371768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
    Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
    Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment.
    Hubalek M; Brunner C; Matthä K; Marth C
    Wien Med Wochenschr; 2010 Nov; 160(19-20):506-12. PubMed ID: 20972709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Her2 a paradigm for targeted therapy].
    Marijon H; André F
    Bull Cancer; 2011 Oct; 98(9):1011-7. PubMed ID: 21684838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 therapy: molecular mechanisms of trastuzumab resistance.
    Nahta R; Esteva FJ
    Breast Cancer Res; 2006; 8(6):215. PubMed ID: 17096862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Her2-positive breast cancer: herceptin and beyond.
    Dean-Colomb W; Esteva FJ
    Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer--loss of PTEN predicts resistance to treatment.
    Pandolfi PP
    N Engl J Med; 2004 Nov; 351(22):2337-8. PubMed ID: 15564551
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
    Menendez JA; Vellon L; Lupu R
    Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
    Spector NL; Blackwell KL
    J Clin Oncol; 2009 Dec; 27(34):5838-47. PubMed ID: 19884552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
    Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D
    Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.
    Nagata Y; Lan KH; Zhou X; Tan M; Esteva FJ; Sahin AA; Klos KS; Li P; Monia BP; Nguyen NT; Hortobagyi GN; Hung MC; Yu D
    Cancer Cell; 2004 Aug; 6(2):117-27. PubMed ID: 15324695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3 kinase activation and response to Trastuzumab Therapy: what's neu with herceptin resistance?
    Park BH; Davidson NE
    Cancer Cell; 2007 Oct; 12(4):297-9. PubMed ID: 17936554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer.
    Mukohara T
    Cancer Sci; 2011 Jan; 102(1):1-8. PubMed ID: 20825420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer.
    Fujita T; Doihara H; Kawasaki K; Takabatake D; Takahashi H; Washio K; Tsukuda K; Ogasawara Y; Shimizu N
    Br J Cancer; 2006 Jan; 94(2):247-52. PubMed ID: 16404430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of trastuzumab resistance and their clinical implications.
    Lan KH; Lu CH; Yu D
    Ann N Y Acad Sci; 2005 Nov; 1059():70-5. PubMed ID: 16382045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to trastuzumab: a necessary evil or a temporary challenge?
    Cardoso F; Piccart MJ; Durbecq V; Di Leo A
    Clin Breast Cancer; 2002 Oct; 3(4):247-57; discussion 258-9. PubMed ID: 12425752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.
    Morris SR; Carey LA
    Oncology (Williston Park); 2006 Dec; 20(14):1763-71; discussion 1771-2, 1774-6. PubMed ID: 17263127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
    Berns K; Horlings HM; Hennessy BT; Madiredjo M; Hijmans EM; Beelen K; Linn SC; Gonzalez-Angulo AM; Stemke-Hale K; Hauptmann M; Beijersbergen RL; Mills GB; van de Vijver MJ; Bernards R
    Cancer Cell; 2007 Oct; 12(4):395-402. PubMed ID: 17936563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.